Cargando…

Delayed cutaneous hypersensitivity reactions following the use of infliximab or adalimumab in patients with coronavirus disease 2019

Recent evidence has emerged concerning delayed cutaneous hypersensitivity reactions after infliximab or adalimumab applications in patients with coronavirus disease 2019 (COVID‐19). A few real‐world studies compared the events, clinical features, and prognosis of infliximab‐ or adalimumab‐related de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing, Yin, Xuedong, Yu, Linlin, Cheng, Weiwei, Wang, Ling, Zhao, Bin, Li, Zhiling, Jing, Xiaoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107992/ https://www.ncbi.nlm.nih.gov/pubmed/36700393 http://dx.doi.org/10.1002/jmv.28518

Ejemplares similares

Delayed Hypersensitivity Reaction to Infliximab Due to Mammalian Meat Allergy
por: González Polanco, Esthermari, et al.
Publicado: (2023)

Infliximab-graded challenge in a patient with Crohn’s disease and adalimumab hypersensitivity
por: Song, Christine H, et al.
Publicado: (2012)

Delayed Cutaneous Hypersensitivity Reactions in Patients With Kaposi's Sarcoma
por: Taylor, J. F., et al.
Publicado: (1974)

Cutaneous Metal Hypersensitivity Reaction
por: Yang, Sun, et al.
Publicado: (2022)

AN ANALYSIS OF THE GENETIC REQUIREMENTS FOR DELAYED CUTANEOUS HYPERSENSITIVITY REACTIONS TO TRANSPLANTATION ANTIGENS IN MICE
por: Streilein, J. Wayne, et al.
Publicado: (1970)

Delayed hypersensitivity to the Comirnaty coronavirus disease 2019 vaccine presenting with pneumonitis and rash
por: Stoyanov, Alex, et al.
Publicado: (2022)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
por: Im, Jong Pil
Publicado: (2017)

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?
por: Kim, Eun Soo
Publicado: (2021)

Adalimumab/infliximab: Lower serologic response: 6 case reports
Publicado: (2022)

Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis
por: Mase, Oliver, et al.
Publicado: (2023)

Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions
por: Schwenck, Johannes, et al.
Publicado: (2019)

Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019
por: Gao, Qian, et al.
Publicado: (2022)

CUTANEOUS HYPERSENSITIVITY REACTIONS TO CELLULAR ISOANTIGENS IN RATS
por: Streilein, J. W., et al.
Publicado: (1967)

Immune cell populations in cutaneous delayed-type hypersensitivity
Publicado: (1983)

Cutaneous Cell-Mediated Delayed Hypersensitivity to Intravitreal Bevacizumab
por: Fam, Anthony, et al.
Publicado: (2020)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
por: Henry, Alistair I, et al.
Publicado: (2011)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis
por: Liu, Jing, et al.
Publicado: (2016)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

IMMUNOLOGICAL SPECIFICITY OF DELAYED AND IMMEDIATE HYPERSENSITIVITY REACTIONS
por: Benacerraf, B., et al.
Publicado: (1962)

Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
por: Carlsen, Arne, et al.
Publicado: (2018)

Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)

Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease
por: Reinisch, Walter, et al.
Publicado: (2020)

Efficacy of infliximab and adalimumab therapy in very early onset, severe ulcerative colitis
por: Rohani, Pejman, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Acute and chronic inflammation alter immunometabolism in a cutaneous delayed-type hypersensitivity reaction (DTHR) mouse model
por: Zizmare, Laimdota, et al.
Publicado: (2022)

Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions
por: Vultaggio, A., et al.
Publicado: (2016)

Adalimumab: Cutaneous leishmaniasis: case report
Publicado: (2022)

Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis
por: Yang, Hua-Hua, et al.
Publicado: (2022)

Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab
por: Tichy, Martin
Publicado: (2019)

Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database
por: Maity, Tuhin, et al.
Publicado: (2021)

Cutaneous hypersensitivity reactions to freshwater cyanobacteria – human volunteer studies
por: Stewart, Ian, et al.
Publicado: (2006)

Multiple drug hypersensitivity associated with severe cutaneous adverse reaction
por: Lin Choo, Karen Jui, et al.
Publicado: (2014)

Sorafenib Induces Delayed-Onset Cutaneous Hypersensitivity: A Case Series
por: Sohn, Kyoung-hee, et al.
Publicado: (2015)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2
por: Sprute, Rosanne, et al.
Publicado: (2021)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Use of Adalimumab in young patients with chronic uveitis in whom infliximab loses its efficacy
por: Giani, TG, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_e6sfbt5e8qgv588hrhfbvm68fm